Search

Displaying results 4491 - 4500 of 6076 in total
  1. Drug

    Aspoxicillin

    go.drugbank.com/drugs/DB13816
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Emodepside

    go.drugbank.com/drugs/DB11403
    InvestigationalVet approved

    Emodepside is an anthelmintic drug that is effective against a number of gastrointestinal nematodes, is licensed for use in cats and belongs to the class of drugs known as the octadepsipeptides, a relatively

  3. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]

  4. Drug

    Lixmabegagene relduparvovec

    go.drugbank.com/drugs/DB16816
    Investigational

    It is under development for the treatment of GM1 gangliosidosis.[L45929]

  5. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    [A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]

  6. Drug

    Enprostil

    go.drugbank.com/drugs/DB13824
    Experimental

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  7. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage.

  8. Drug

    AAV-AIPL

    go.drugbank.com/drugs/DB17857
    Experimental

    Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.

  9. Drug

    Fiztasovimab

    go.drugbank.com/drugs/DB24033
    Investigational

    [A278004, A278005] NPC-21 is under investigation in clinical trial NCT04225923 (A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection).

  10. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.